ARA-290 Research

At a Glance

• What it is: A lab-made peptide engineered from a region of erythropoietin (EPO), built to activate a tissue-protective signaling pathway without EPO’s effect on red blood cells.
• Researchers have studied it for: sarcoidosis-associated small fiber neuropathy, in two human trials, plus mechanism work in inflammation and wound-healing research models.
• Evidence level: Real human trial data exists, in one specific rare-disease population. The company that ran those trials, Araim Pharmaceuticals, has since ceased operations, and no Phase III trial was ever completed.
• The short version: ARA-290 has real, published human trial data behind it, which is genuinely uncommon in this category. That data is narrow: one disease population, one structural endpoint, and a development program that stopped before full approval. This is a research summary, not a reason to use anything.

ARA-290, also called Cibinetide, is a peptide built from the helix-B surface region of erythropoietin, the part of the molecule tied to tissue protection rather than red blood cell production. Researchers designed it to activate that protective signaling on its own, separate from EPO’s better-known blood effects.

A quick note on framing. Both human trials discussed below studied people with sarcoidosis, a rare inflammatory disease, and specifically those with small fiber neuropathy symptoms from it. Neither trial studied healthy adults. We cite that literature below as research. None of it is a suggestion to use anything.

What researchers have studied

Pilot trial in sarcoidosis-associated neuropathy (2013). A randomized, double-blind, placebo-controlled study in 22 adults with sarcoidosis and small fiber neuropathy symptoms. Researchers gave ARA-290 by IV, three times a week for four weeks, and measured a standard neuropathy symptom score. The treatment group improved significantly more than placebo. PMID 23168581. https://pubmed.ncbi.nlm.nih.gov/23168581/

Phase 2b trial, the larger follow-up (Investigative Ophthalmology & Visual Science, 2017). A randomized, placebo-controlled trial in 64 people with the same underlying condition. They took placebo or one of three daily injected doses (1mg, 4mg, or 8mg) for 28 days. Researchers measured corneal nerve fiber area, a structural marker of small nerve fiber loss, using corneal confocal microscopy. The trial met its main goal at the 4mg dose, with roughly a 23% increase in nerve fiber area compared with baseline. PMID 28475703. https://pubmed.ncbi.nlm.nih.gov/28475703/

How it works

Erythropoietin (EPO) is best known for telling the body to make red blood cells. Separately, it can activate a different signaling pathway tied to tissue protection and repair, through a receptor pairing researchers call the Innate Repair Receptor, built from EPOR and a second receptor called CD131.

ARA-290 is built to activate that second pathway specifically, without triggering the red-blood-cell effect. In research models, that activation has been linked to reduced inflammatory signaling and improved tissue repair measures. Because it targets a specific receptor pairing rather than acting broadly, researchers class it as a selective Innate Repair Receptor agonist.

What the research does not establish

Read this part twice. The honest limits matter more than the headlines.

• The company that ran both human trials, Araim Pharmaceuticals, has ceased operations. ARA-290 received orphan drug status for this condition but was never taken to full FDA approval, and no larger confirming trial was ever completed. Nothing about this compound is on an active development path today.
• Both trials studied one rare disease population. Researchers have not established these results in healthy adults, athletes, or the general public.
• The trials tracked a structural nerve marker and a symptom score over four weeks. They were not built to show broad nerve-health or recovery outcomes in people without this condition.
• Mechanism research exists in animal models of inflammation and wound healing. Those are research-model findings, not human outcomes.
• This page is a research summary only. It does not say the compound does anything “for you.”

Buyer-intent tag

Neuropathic research / Tissue-protective signaling

Further reading: for the full mechanism deep-dive, including receptor-level detail and two additional animal studies, see ARA-290 (Cibinetide): The Innate Repair Receptor and What Its Trials Actually Showed.

For Research Use Only. Not for human consumption. Etched Research supplies compounds for laboratory and research use only. Nothing on this page is medical advice, a health claim, or a recommendation to use.